A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression-Reference-Cited by-同舟云学术

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

Published:2022-01 Issue: Volume:296 Page:549-558
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Loebel Antony,Koblan Kenneth S.,Tsai Joyce,Deng Ling,Fava Maurizio,Kent Justine,Hopkins Seth C.

Funder

Sunovion

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference62 articles.

1. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo;Abbas;Psychopharmacology (Berl.),2009

2. American Psychiatric Association, 2013. Anxiety disorders. In Diagnostic and Statistical Manual of Mental Disorders (5th ed.).

3. The barnes akathisia rating scale – revisited;Barnes;J Psychopharmacology,2003

4. Epidemiology of DSM-5 bipolar i disorder: results from the national epidemiologic survey on alcohol and related conditions–iii;Blanco;J. Psychiatr. Res.,2017

5. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder;Bonaventure;J. Pharmacol. Exp. Ther.,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enrichment using speech latencies improves treatment effect size in a clinical trial of bipolar depression;Psychiatry Research;2024-10

2. Evaluating speech latencies during structured psychiatric interviews as an automated objective measure of psychomotor slowing;Psychiatry Research;2024-10

3. A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression;Contemporary Clinical Trials;2024-10

4. DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects;Psychopharmacology;2024-06-10

5. Discovery and Model‐Informed Drug Development of a Controlled‐Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain;Clinical Pharmacology & Therapeutics;2024-05-31